National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 67378 [2010-27569]
Download as PDF
<![CDATA[
67378
Federal Register / Vol. 75, No. 211 / Tuesday, November 2, 2010 / Notices
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Administration,
Office of Information Services, 370
L’Enfant Promenade, SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. E-mail address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Dated: October 28, 2010.
Robert Sargis,
Reports Clearance Officer.
Special Emphasis Panel, Ancillary Study in
Necrotizing Enterocolitis.
Date: December 1, 2010.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call)
Contact Person: Maria E. Davila-Bloom,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 758, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davilabloomm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 26, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–27569 Filed 11–1–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No FDA–2010–N–0001]
Pediatric Advisory Committee; Notice
of Meeting
[FR Doc. 2010–27596 Filed 11–1–10; 8:45 am]
BILLING CODE 4184–01–P
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
hsrobinson on DSK69SOYB1PROD with NOTICES
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
VerDate Mar<15>2010
18:39 Nov 01, 2010
Jkt 223001
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Pediatric
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 7, 2010, from 8 a.m.
to 6 p.m.
Location: Bethesda Marriott Hotel,
5151 Pooks Hill Rd., Bethesda, MD
20814.
Contact Person: Walter Ellenberg,
Office of Pediatric Therapeutics, Office
of Special Medical Programs, Office of
the Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg 32, rm. 5154, Silver Spring,
MD 20993, 301–796–0885, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Washington, DC area), code
8732310001. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The Pediatric Advisory
Committee will meet to discuss
pediatric-focused safety reviews, as
mandated by the Best Pharmaceuticals
for Children Act and the Pediatric
Research Equity Act, for Prevista
(darunavir ethanolate), PegIntron
(peginterferon alfa–2b), Xyzal
(levocetirizine dihydrochloride) tablet
and solution, Flovent HFA (fluticasone
propionate), Acanya Gel (clindamycin/
benzoyl peroxide combination), Epiduo
Gel (adapalene and benzoyl peroxide),
Ulesfia Lotion 5% (benzyl alcohol),
Axert (almotriptan), Gardasil (human
papillomavirus quadrivalent types 6, 11,
16, 18, vaccine recombinant), Lamictal
and Lamictal XR (lamotrigine), and
Neulasta (pegfilgrastim). The committee
will also receive a followup on
Depakote ER (divalproex sodium).
Committee members who participated
in the Cardiovascular and Renal Drugs
Advisory Committee and the
Gastrointestinal Drugs Advisory
Committee meetings held on July 29,
2010, and November 5, 2010,
respectively, will provide a brief
summary of the meetings.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 29, 2010.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
E:\FR\FM\02NON1.SGM
02NON1
]]>Agencies
[Federal Register Volume 75, Number 211 (Tuesday, November 2, 2010)]
[Notices]
[Page 67378]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-27569]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Ancillary Study in
Necrotizing Enterocolitis.
Date: December 1, 2010.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference Call)
Contact Person: Maria E. Davila-Bloom, PhD, Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-7637, davila-bloomm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: October 26, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-27569 Filed 11-1-10; 8:45 am]
BILLING CODE 4140-01-P
